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Summary
Epidemiology studies and clinical trials have suggested that
the use of non-steroidal anti-inflammatory drugs (NSAIDs),
including aspirin, can significantly reduce the incidence of
and mortality associated with many cancers [1–3], and upre-
gulation of the COX2-PGE2 pathway in tumor microenviron-
ments might drive several aspects of cancer progression
[4–6]. For these reasons, the mechanisms linking COX
blockade and cancer prevention have long been an area of
active investigation [7]. During carcinogenesis, COX-2 is
expressed both by malignant epithelial cells [8, 9] and by
tumor-associated stromal cells, including macrophages
[10–12], but the observation that NSAIDs are most effective
in cancer prevention in APCmin/+ mice if the mice are treated
from conception [13] suggests that the COX-2/PGE2 pathway
might also be critical at the earliest stages of tumor develop-
ment. In this study we take advantage of the translucency
and genetic tractability of zebrafish larvae to investigate
the involvement of inflammatory cells at cancer initiation,
when transformed cells first arise in tissues. We previously
showed that innate immune cells supply early transformed
cells with proliferative cues [14] and, by using complemen-
tary pharmacological and genetic experiments, we now
show that prostaglandin E2 (PGE2) is the trophic signal
required for this expansion of transformed cells. Our in vivo
observations at these early stages of cancer initiation
provide a potential mechanistic explanation for why long-
term use of low doses of NSAIDs, including aspirin, might
reduce cancer onset.
Results and Discussion
We have used a human HRASG12V-driven transgenic zebrafish
cancer model, in which mucous-secreting cells (analogous to
human goblet cells) in the skin are transformed by an eGFP-
HRASG12V fusion protein. Using thismodel, we have previously
shown with a live imaging approach that HRASG12V (hereafter
referred to as V12RAS)-expressing transformed cells induce
a robust inflammatory response immediately after their emer-
gence in host skin [14]. Paradoxically, the recruited innate
immune cells play a trophic role in promoting the growth of
transformed cells [14]. To test whether the COX-2/PGE2
pathway might be involved in this process, we decided to
block PGE2 production.
Blocking PGE2 Synthesis Retards the Growth of
Transformed Cells
PGE2 is one of the most abundant PGs produced in the body
and plays key roles in mediating the inflammatory response
[7, 15]. Cyclooxygenase 1 and 2 (COX-1 and COX-2) catalyze
the rate-limiting step in PGE2 synthesis by converting arachi-
donic acid into prostaglandin H2, which is subsequently con-
verted to prostaglandins (PGs) via the actions of specific PG
synthases (Figure 1A). COX-1 is the housekeeping enzyme
that generates PGE2 under normal conditions. COX-2 is
induced under inflammatory conditions and generates PGE2
via mPGES at the site of immune cell recruitment (Figure 1A).
Zebrafish have three COX enzymes, zfCOX-1, zfCOX-2a,
and zfCOX2-b [16, 17], and two PGE2 synthases, cytosolic
PGE2 synthase (cPGES) and microsomal PGE2 synthase
(mPGES) [18]. Because zebrafish larvae are amenable to
chemical treatment, we first took a pharmacological approach
to suppress PGE2 production (as outlined in Figure 1B).
Suppression of COX-2 by either NS398 or Celecoxib led to
a significant reduction in the number of V12RAS+ cells (Fig-
ure 1C; Figure S1 in the Supplemental Information available
online) without altering expression levels of endogenous kit
a (the transgene driver) or having adverse effects on larval
development (Figure S1). Moreover, ectopically added
dmPGE2 (a stable analog of PGE2) partially restored the
number of transformed cells in COX-2-inhibitor-treated larvae
(Figures 1D and 1E; Figure S1). No significant reduction in the
number of V12RAS+ cells was seen in larvae treated with the
COX-1 inhibitor SC560 (Figure 1C). These data suggest that
in zebrafish, COX-2-mediated production of PGE2 promotes
the growth of transformed cells.
To establish whether PGE2 was indeed the main tumor-
promoting mediator generated by COX-2 in our model, we
used CAY10560, another inhibitor specific to mPGES, which
is known to be downstream of COX-2 in generating PGE2 in
zebrafish [18].Again,wesawa reduction in thenumberof trans-
formed cells; dmPGE2was able to restore the number of trans-
formed cells in combined treatmentwithCAY10560 (Figure 1F).
Both V12RAS+-Transformed Cells and Recruited
Leukocytes Express COX-2, but Only Leukocytes Express
mPGES
In mammals, both cancer cells and stromal cells can upregu-
late COX-2 [8–11], although the contribution of immune-cell-
derived PGE2 in tumor progression has not yet been defined
[5]. We wanted to identify which cell lineages expressed
PGE2-generating enzymes at the earliest tumor-initiation
stage. Double immunostaining showed that both V12RAS+
cells (transformed cells) and most L-plastin+ cells (neutrophils
and macrophages) expressed COX-2 (Figures 1H and 1I).
However, we could only detect a signal for mPGES antibody
in a subset (approximately 20%) of the recruited leukocytes
and in none of the transformed cells (Figures 1J and 1K). These
expression profiles imply that, at this early stage, only leuko-
cytes generate PGE2.
*Correspondence: v1yfeng2@staffmail.ed.ac.uk (Y.F.), paul.martin@bristol.
ac.uk (P.M.)
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Morpholino Knockdown of mPGES Expression Confirms
that PGE2 Is Required for V12RAS
+ Overgrowth
Our inhibitor data had demonstrated that COX-2-mPGES-
derived PGE2 was important for V12RAS
+ cell growth. To
confirm these findings, we used antisense morpholinos to
genetically knock down PGE2 production. Zebrafish have
two genes encoding COX-2 but only one encoding mPGES.
Moreover, mPGES only catalyzes PGE2 production, and
so we used a previously published mPGES morpholino to
block its expression [19] (Figure S2). Unfortunately, mPGES-
mediated PGE2 is required for cell movements during epiboly
[19]. To bypass this problem, we rescued normal early
development of mPGES morphants by incubating them in
dmPGE2.Then, after epiboly, we transferred half of the mor-
phants into fresh medium without dmPGE2 at 48 hr post-fertil-
ization (hpf; Figure S3); V12RAS+ cell numbers were analyzed
at 4.5 days post-fertilization (dpf). Again, we saw a reduction
in the number of V12RAS+ cells in mPGES morphants
compared with control-morpholino-injected larvae (Figures
1G, 1L, and 1M), but the number of V12RAS+ cells was partially
restored in those mPGES morphants that continued with
dmPGE2 treatment (Figures 1G, 1L, and 1N).
In summary, both our pharmacological inhibition and
genetic mPGES knockdown data suggest that PGE2 plays an
important role in promoting the growth of V12RAS+-trans-
formed cells, and our immunostaining data suggest that
recruitment of immune cells might be the main source of
PGE2 at this stage. However, because ectopic dmPGE2 failed
to completely restore the growth of transformed cells to
control levels in either our pharmacological-inhibition or
genetic-knockdown experiments, it seems likely that there
are also some PGE2-independent influences on the growth
of transformed cells.
PGE2 Directly Promotes the Growth of Transformed Cells
via the EP1 Receptor
To address whether PGE2 exerts a direct effect on the growth
of transformed cells, we next focused on which of the PGE2
receptors was expressed by the transformed cells to mediate
such a response. Our immunostaining data indicate that, of the
Figure 1. Blocking COX-2-mPGES-Mediated PGE2 Production Suppresses the Growth of V12RAS
+ Transformed Cells In Vivo
(A) A schematic representation of PGE2 production through the COX-2 pathway indicates the targets and inhibitors used in this study.
(B) A schematic representation of our pharmacological treatment regime and clonal analysis of transformed cells (green) in V12RAS+-cell-bearing larvae.
A yellow box indicates the flank skin region in which we quantified alterations in growth of V12RAS+ cells.
(C–G) Graphic comparisons of V12RAS+ cell numbers in larval flank skin region after various treatments; (C) larvae treated with DMSO, COX-1 inhibitor,
SC-560, and the COX-2 inhibitors NS398 and Celecoxib (p < 0.01, n = 22, 27, and 32, respectively); (D) larvae treated with DMSO, NS398, and NS398
+dmPGE2 (p < 0.001, n = 56, 51, and 40, respectively); (E) larvae treated with DMSO, Celecoxib, and Celecoxib +dmPGE2 (p < 0.001, n = 61, 42, and 42,
respectively); (F) larvae treated with DMSO, CAY10560 and CAY10560 +dmPGE2 (p < 0.001, n = 45, 42, and 46, respectively); (G) Control morphants, mPGES
morphants, and mPGES morphants rescued with dmPGE2 (p < 0.001, n = 26, 25, and 25, respectively).
(H) Immunostaining for COX-2 (blue) indicates that both leukocytes (anti-L-plastin [red]) and V12RASeGFP+ transformed cells (green) express COX-2.
(I) Single-channel image of (H), better showing COX-2 expression; green and red arrows indicate transformed cells and leukocytes, respectively.
(J) Immunostaining for mPGES (blue) indicates its expression by some leukocytes (anti-L-plastin; red arrow) but not transformed cells (green).
(K) Single-channel image of (J).
(L–N) Representative images of flank skin regions showing V12RAS+ clones (green) of (L) control morphant, (M)mPGESmorphant, and (N)mPGESmorphant
supplemented with dmPGE2- Scale bars represent 20 mm (H and I), 15 mm (J and K), and 100 mm (L–N). See also Figures S1, S2, and S3.
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five PGE2 receptors that exist in the zebrafish genome
(ENSEMBL Zv9), only EP1 is highly expressed by the trans-
formedcells (Figures 2A–2C) andhasaparticularly pronounced
perinuclear localization, as previously reported for EP1
receptor localization in tissue cultured mammalian cells [20].
To test whether EP1 receptor was responsible for mediating
the PGE2 signal in transformed cells, we used two EP1-specific
inhibitors, SC19220 and ONO-8711 (Cayman Chemicals),
and both treatments led to a significant reduction in the
growth of transformed cells in vivo (Figures 2D and 2E) without
adverse effects on larval development (Figure S1). It is thus
likely that PGE2 promotes the growth of transformed cells
through the EP1 receptor.
An Ectopic Supplement of dmPGE2 Can Partially Restore
V12RAS+ Cell Growth in Leukocyte-Depleted Larvae
Our data herein suggest that PGE2 is produced by leuko-
cytes as trophic support for the growth of transformed cells.
If this is indeed the case, then we should be able to
restore tumor growth in leukocyte-depleted larvae by adding
PGE2. We thus blocked leukocyte development by using
a combined morpholino pu.1+gcsfr double knockdown,
which effectively arrests all myeloid lineage development
in zebrafish larvae until at least 4 dpf [21]. Leukocyte deple-
tion does not affect general embryo development (Fig-
ure S4A–S4G); however, this absence of leukocytes led to
a dramatic reduction in the number of V12RAS+ cells
(Figures 3B and 3J). When we supplied dmPGE2 to the
leukocyte-depleted double morphants, we saw a partial
restoration of V12RAS+ cell numbers (Figures 3C and 3J).
These data suggest that immune cell trophic support is
Figure 2. PGE2 Promotes Growth of Trans-
formed Cells via the EP1 Receptor
(A–C) Immunostaining for EP1 receptor showing
EP1 (magenta) localized within V12RASeGFP+
cells (green); nuclei are stained with Hoechst
33342 (blue), and leukocytes are revealed by im-
munostaining with anti-L-plastin antibody (red).
EP1 receptor (magenta) shows perinuclear local-
ization (white arrows in [B] and [C]); a pair of
recently divided daughter transformed cells
exhibit faint EP1 staining (yellow arrows in [B]
and [C]), and a transformed cell at metaphase
shows no EP1 signal (white arrowhead in [C]).
Scale bars represent 10 mm.
(D) Graphic illustration showing that EP1 receptor
antagonist SC19220 leads to a reduction in the
number of transformed cells (p < 0.05, n = 38
and 35).
(E) The same is true for the EP1 receptor antago-
nist ONO-1811 (p < 0,001, n = 20 and 21).
See also Figure S1.
mediated through the PGE2-EP1
receptor pathway, which acts directly
on the transformed cells.
dmPGE2 Fully Restores V12RAS
+
Cell Numbers in Macrophage-
Depleted Larvae but Only Partially
Does So in Neutrophil-Deficient
Larvae
In our previous studies, we found
that the transformed cells trigger
recruitment of several innate immune cell lineages [14]. We
now wished to dissect the contribution of individual leukocyte
lineages to the growth of transformed cells. In zebrafish,
neutrophil development is severely impaired in gcsfr-morpho-
lino-injected larvae, whereas macrophage numbers are only
slightly decreased [21] (Figure S4K). In such neutrophil-
depleted morphants, we observed that V12RAS+ cell numbers
are reduced almost to the numbers seen in pu.1+gcsfr mor-
phants (which lack both neutrophils and macrophages;
Figures 3B and 3D; Figure S4I). This suggests an important
trophic role for neutrophils during the initial expansion of
transformed cells.
IRF8 is a transcription factor that regulates the differentia-
tion of a common progenitor into macrophages rather than
neutrophils, and irf8 morpholino treatment depletes macro-
phages and results in a compensatory increase in neutrophils
[22] (see Figure S4J). In these macrophage-depleted larvae,
we again saw a reduction in the number of V12RAS+ cells
(reduced to 41.9%) but to a much lesser degree than in total
leukocyte (pu1+gcsfr morphant, macrophage + neutrophil)-
depleted larvae (reduced to 21.1%) (Figures 3B, 3F, and 3J).
We confirmed that macrophage depletion alone (i.e., without
a compensatory increase in neutrophils) also leads to a reduc-
tion in the number of V12RAS+ cells number (reduced to 49%)
by using low-dose pu.1morpholino (Figures 3H and 3L). These
data suggest that macrophages contribute to the trophic
support of transformed cells but to a lesser extent than
neutrophils.
Moreover, the nature of trophic support received from
neutrophils could be qualitatively different from that received
from macrophages. When dmPGE2 was used to treat larvae
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that had been depleted of different immune cell types, we saw
differences in the rescue profile of transformed-cell growth. In
both pu.1+gcsfr double morphants (lacking both macro-
phages and neutrophils) and gcsfr morphants (lacking only
neutrophils), dmPGE2 only partially restored V12RAS
+ cell
numbers (Figures 3C, 3E, 3J, and 3K). However, in macro-
phage-depleted irf8morphants and low-dose pu.1morphants,
dmPGE2 treatment completely restored the number of trans-
formed cells (Figures 3G, 3I, 3L, and 3M). It has previously
been shown that PGE2 can drive hematopoietic stem cell
expansion [23], and so we tested whether leukocyte rescue
by dmPGE2 treatment might indirectly cause increased
numbers of transformed cells, but we saw no significant
recovery of depleted innate immune cells in these larvae
(Figures S4I–S4N). These findings suggest that macrophages
contribute PGE2 alone, whereas neutrophils might produce
other trophic factor(s).
Reduced PGE2 Production Leads to Altered Neutrophil
Migration in the Vicinity of Transformed Cells, and
Increased Cell Death of Transformed Cells Follows along
with Their Rapid Engulfment by Macrophages
It has been shown that PGE2 regulates immune cell function,
and several recent reports suggest that PGE2 might induce
an immunosuppressive phenotype in leukocytes [24–26]. We
wondered whether suppressing PGE2 production with COX-2
inhibitors might modulate the early inflammatory response
and change the way in which leukocytes and transformed cells
interact.
Cell-tracking analysis of time-lapse movies show that in
COX-2 inhibitor (NS398)-treated larvae, neutrophils near
clones of transformed cells show considerably reduced
motility (migration velocity drops from 0.125 6 0.046 mm to
0.054 6 0.038 mm, [mean 6 SD]) (Figures 4A, 4A0, 4B, 4B0,
and 4C; also seeMovie S1) in comparison to those in untreated
Figure 3. Leukocyte Depletion Prevents V12RAS+ Cell Growth, which Can Be Partially Rescued by dmPGE2
(A–I) Representative images of flank skin regions illustrating numbers of V12RASeGFP+ transformed cells after morpholino (Mo) knockdown of pu.1 and
gcsfr (for depletion of both neutrophils and macrophages); gcsfr alone (for depletion of neutrophils); irf8 or a lower dose (2 nl/embryo) of pu.1 morpholino
alone (for depletion of macrophages) with or without additional treatment with dmPGE2.
(J) Graphic illustration of how dmPGE2 can rescue the number of transformed cells in morphants in which both neutrophils and macrophages have been
specifically depleted (p < 0.01, n = 33, 32, and 34).
(K) Graphic illustration of how dmPGE2 can only partially rescue morpholino knockdowns that largely target neutrophils (p < 0.001, n = 25, 25, and 22).
(L andM) Similar graphic illustration of how dmPGE2 can rescuemorpholino knockdowns that largely target macrophages (irf8 Mo—p < 0.05, n = 24, 26, and
23; 2 nl pu.1 Mo—p < 0.05, n = 31, 30, and 34).
The scale bar represents 100 mm. See also Figures S3 and S4.
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transformed-cell-bearing larvae, indicating that reduced PGE2
does indeed lead to a change in neutrophil behavior.
Live-imaging studies by us and others have defined the
‘‘inflammatorymacrophage’’ in zebrafish larvae by their typical
elongated, dendritic morphology and slow patrolling behavior
[14, 27]. Here we used Tg (NFkB-RE:eGFP; LysC:DsRed; kit
a:GalTA4;UAS:eGFPV12RAS) larvae, in which macrophages
are labeled with low levels of NFkb reporter GFP (Figure 4D;
also seeMovie S2) to reveal their behavior near clones of trans-
formed cells. In untreated larvae, transformed-cell deaths are
sufficiently rare that we have never captured them by live
imaging in either the presence or the absence of immune cells
[14]. By contrast, in larvae treated with COX-2 inhibitor
(NS398), we frequently saw transformed-cell deaths, and often
thesewere associatedwith priormacrophage encounters (Fig-
ure 4D; see also Movie S2). The corpses of transformed cells
were subsequently rapidly cleared away by adjacent macro-
phages. These data suggest that reduction of PGE2 levels by
COX-2 inhibition leads to a change of macrophage behavior
and enhanced proinflammatory activity, which results in
a more active engagement and engulfment of transformed
cells. This is consistent with recent reports that PGE2 directs
macrophages toward a tumor-promoting M2 phenotype
[24, 28] and can redirect dendritic cells toward a stable
myeloid-derived-suppressor-cell phenotype [25].
Our previous and current studies reveal a pivotal contribu-
tion of host immune cells to the optimal growth of transformed
cells as they first arise in tissues [14]. Here we show that leuko-
cyte-derived PGE2 is a key trophic factor for transformed cells
at these early stages of cancer initiation. Our data suggest that
PGE2might work in two complementary ways, both directly on
transformed cells via the EP1 receptor and indirectly by
promoting a ‘‘trophic inflammatory cell’’ behavior in neutro-
phils and macrophages; this behavior might also support the
survival of transformed cells by inhibiting killing and
engulfment.
We have provided evidence here that a trophic inflammatory
response is important for a transformed cell to grow at its
inception and that PGE2 produced by innate immune cells via
the COX-2 pathway is a key trophic factor for optimal growth
of transformedcells at theearliest stagesof tumorprogression.
Moreover, this trophic inflammatory response can be sup-
pressed by the inhibition of PGE2 production via COX-2
inhibitors, which might explain why use of non-steroidal anti-
inflammatory drugs (NSAIDs) can reduce cancer incidence.
Experimental Procedures
Zebrafish Strains and Maintenance
Adult zebrafish (Danio rerio) weremaintainedaspreviously described [29]. All
experimentswereconductedwith local ethical approval fromtheUniversityof
Bristol and in accordance with UK Home Office regulations. Strains included
Tg(5XUAS:eGFP-H-RASV12)io6 [30], Et(kit a:GalTA4,UAS:mCherry)hzm1
[30], Tg(LysC:DsRed)nz [31]; the Tg(NFkB-RE:eGFP)i235 line was generated
with the method and constructs described in Kanther et al. [32].
Figure 4. Live Imaging Reveals that Reduced PGE2 Levels as a Result of COX-2 Inhibition Lead to Leukocyte Behavior Change and Increased Transformed-
Cell Death
(A and B) Still images frommovies illustrating neutrophil (red) numbers and their motility in the vicinity of V12RAS transformed cells (green) in (A) control and
(B) NS398-treated larvae (images are taken fromMovie S1) (A0 and B0) show the tracks over 100 min of neutrophil movements from the two movies S1A and
S1B, respectively, revealing reduced neutrophil motility in NS398-treated (B0) compared with control (A0) larva. Scale bars represent 50 mm.
(C) Quantification of neutrophil migration velocity (V = mean 6 SD); DMSO-treated V = 0.125 6 0.046 mm (n = 39); NS398-treated V = 0.054 6 0.038 mm
(n = 32).
(D) A series of still images from a time-lapse movie (see Movie S2) showing transformed-cell death associated with a macrophage encounter in a larva
treated with NS398; subsequently, this macrophage and others engulf the resulting cell debris. Red arrows in (i)–(iv) indicate a macrophage labeled by
NFkB-RE:eGFP (pale green). Purple arrow in (v) indicates a macrophage engulfing the transformed-cell debris and forming a phagosome inside its cell
body. The scale bar represents 15 mm.
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Morpholino Injection
All morpholinos were obtained from (GeneTools LLC, Philomath, OR, USA)
and injected into one-cell-stage embryos as previously described [19, 21,
22, 33]. For sequence information, see Supplemental Experimental
Procedures.
Immunofluorescence, Live Imaging, and Tracking of Cell Movements in
Larvae
Whole-mount immunostaining was performed as previously described [14].
For all our live-imaging studies, time-lapse movies were collected with a
Leica SP5-AOBS Confocal Laser-Scanning Microscope. An Image J 1.4,
Manual Tracking plugin was used for cell tracking (further details are avail-
able in the Supplemental Experimental Procedures).
Pharmacological Treatment and Clonal Analysis of the Progression of
Transformed Cells
Transformed-cell-bearing larvae were treated with inhibitors of PGE2-
synthesis enzymes or dmPGE2 from 48 hpf to 88 hpf or from 48 hpf to 96
hpf in 0.3% Danieau’s solution containing 1% DMSO. All the inhibitors
were from Cayman Chemicals. For detailed procedures, see Supplemental
Experimental Procedures.
Statistics
All the data were analyzed (Prism 4.1, GraphPad Software, La Jolla, CA,
USA) with an unpaired two-tailed Student’s t test for comparisons between
two groups with a one-way ANOVA and appropriate post-test adjustment
for comparisons of multiple groups.
Supplemental Information
Supplemental Information includes four figures, two movies, and Supple-
mental Experimental Procedures and can be found with this article online
at doi:10.1016/j.cub.2012.05.010.
Acknowledgments
We thank Chris Paraskeva and Helena Smartt for useful discussions during
the preparation of our manuscript and Nikolay Ogryzko for generation of the
NFkB line; this studywas funded by aWellcome Trust program grant to P.M.
Received: March 1, 2012
Revised: April 10, 2012
Accepted: May 2, 2012
Published online: May 31, 2012
References
1. Rothwell, P.M., Wilson, M., Elwin, C.E., Norrving, B., Algra, A., Warlow,
C.P., and Meade, T.W. (2010). Long-term effect of aspirin on colorectal
cancer incidence and mortality: 20-year follow-up of five randomised
trials. Lancet 376, 1741–1750.
2. Ruder, E.H., Laiyemo, A.O., Graubard, B.I., Hollenbeck, A.R., Schatzkin,
A., and Cross, A.J. (2011). Non-steroidal anti-inflammatory drugs and
colorectal cancer risk in a large, prospective cohort. Am. J.
Gastroenterol. 106, 1340–1350.
3. Liao, L.M., Vaughan, T.L., Corley, D.A., Cook, M.B., Casson, A.G.,
Kamangar, F., Abnet, C.C., Risch, H.A., Giffen, C., Freedman, N.D.,
et al. (2012). Nonsteroidal anti-inflammatory drug use reduces risk of
adenocarcinomas of the esophagus and esophagogastric junction in
a pooled analysis. Gastroenterology 142, 442–452, e5, quiz e22–e23.
4. Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-
related inflammation. Nature 454, 436–444.
5. Greenhough, A., Smartt, H.J., Moore, A.E., Roberts, H.R.,Williams, A.C.,
Paraskeva, C., and Kaidi, A. (2009). The COX-2/PGE2 pathway: key roles
in the hallmarks of cancer and adaptation to the tumour microenviron-
ment. Carcinogenesis 30, 377–386.
6. Soumaoro, L.T., Uetake, H., Higuchi, T., Takagi, Y., Enomoto, M., and
Sugihara, K. (2004). Cyclooxygenase-2 expression: A significant prog-
nostic indicator for patients with colorectal cancer. Clin. Cancer Res.
10, 8465–8471.
7. Wang, D., and Dubois, R.N. (2010). Eicosanoids and cancer. Nat. Rev.
Cancer 10, 181–193.
8. Glover, J.A., Hughes, C.M., Cantwell, M.M., and Murray, L.J. (2011). A
systematic review to establish the frequency of cyclooxygenase-2
expression in normal breast epithelium, ductal carcinoma in situ, micro-
invasive carcinoma of the breast and invasive breast cancer. Br. J.
Cancer 105, 13–17.
9. Elder, D.J., Baker, J.A., Banu, N.A., Moorghen, M., and Paraskeva, C.
(2002). Human colorectal adenomas demonstrate a size-dependent
increase in epithelial cyclooxygenase-2 expression. J. Pathol. 198,
428–434.
10. Hull, M.A., Booth, J.K., Tisbury, A., Scott, N., Bonifer, C., Markham, A.F.,
and Coletta, P.L. (1999). Cyclooxygenase 2 is up-regulated and local-
ized to macrophages in the intestine of Min mice. Br. J. Cancer 79,
1399–1405.
11. Bamba, H., Ota, S., Kato, A., Adachi, A., Itoyama, S., and Matsuzaki, F.
(1999). High expression of cyclooxygenase-2 in macrophages of human
colonic adenoma. Int. J. Cancer 83, 470–475.
12. Williams, C.S., Tsujii, M., Reese, J., Dey, S.K., and DuBois, R.N. (2000).
Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest.
105, 1589–1594.
13. Sansom, O.J., Stark, L.A., Dunlop, M.G., and Clarke, A.R. (2001).
Suppression of intestinal and mammary neoplasia by lifetime adminis-
tration of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(-/-) mice.
Cancer Res. 61, 7060–7064.
14. Feng, Y., Santoriello, C., Mione, M., Hurlstone, A., and Martin, P. (2010).
Live imaging of innate immune cell sensing of transformed cells in
zebrafish larvae: Parallels between tumor initiation and wound inflam-
mation. PLoS Biol. 8, e1000562.
15. Hata, A.N., and Breyer, R.M. (2004). Pharmacology and signaling of
prostaglandin receptors: multiple roles in inflammation and immune
modulation. Pharmacol. Ther. 103, 147–166.
16. Grosser, T., Yusuff, S., Cheskis, E., Pack, M.A., and FitzGerald, G.A.
(2002). Developmental expression of functional cyclooxygenases in
zebrafish. Proc. Natl. Acad. Sci. USA 99, 8418–8423.
17. Ishikawa, T.O., Griffin, K.J., Banerjee, U., and Herschman, H.R. (2007).
The zebrafish genome contains two inducible, functional cyclooxyge-
nase-2 genes. Biochem. Biophys. Res. Commun. 352, 181–187.
18. Pini, B., Grosser, T., Lawson, J.A., Price, T.S., Pack, M.A., and
FitzGerald, G.A. (2005). Prostaglandin E synthases in zebrafish.
Arterioscler. Thromb. Vasc. Biol. 25, 315–320.
19. Cha, Y.I., Kim, S.H., Sepich, D., Buchanan, F.G., Solnica-Krezel, L., and
DuBois, R.N. (2006). Cyclooxygenase-1-derived PGE2 promotes cell
motility via the G-protein-coupled EP4 receptor during vertebrate
gastrulation. Genes Dev. 20, 77–86.
20. Bhattacharya, M., Peri, K.G., Almazan, G., Ribeiro-da-Silva, A., Shichi,
H., Durocher, Y., Abramovitz, M., Hou, X., Varma, D.R., and Chemtob,
S. (1998). Nuclear localization of prostaglandin E2 receptors. Proc.
Natl. Acad. Sci. USA 95, 15792–15797.
21. Liongue, C., Hall, C.J., O’Connell, B.A., Crosier, P., and Ward, A.C.
(2009). Zebrafish granulocyte colony-stimulating factor receptor
signaling promotes myelopoiesis and myeloid cell migration. Blood
113, 2535–2546.
22. Li, L., Jin, H., Xu, J., Shi, Y., and Wen, Z. (2011). Irf8 regulates macro-
phage versus neutrophil fate during zebrafish primitive myelopoiesis.
Blood 117, 1359–1369.
23. Durand, E.M., and Zon, L.I. (2010). Newly emerging roles for prosta-
glandin E2 regulation of hematopoiesis and hematopoietic stem cell
engraftment. Curr. Opin. Hematol. 17, 308–312.
24. Heusinkveld, M., de Vos van Steenwijk, P.J., Goedemans, R.,
Ramwadhdoebe, T.H., Gorter, A., Welters, M.J., van Hall, T., and van
der Burg, S.H. (2011). M2 macrophages induced by prostaglandin E2
and IL-6 from cervical carcinoma are switched to activated M1 macro-
phages by CD4+ Th1 cells. J. Immunol. 187, 1157–1165.
25. Obermajer, N., Muthuswamy, R., Lesnock, J., Edwards, R.P., and
Kalinski, P. (2011). Positive feedback between PGE2 and COX2
redirects the differentiation of human dendritic cells toward stable
myeloid-derived suppressor cells. Blood 118, 5498–5505.
26. Kalinski, P. (2012). Regulation of immune responses by prostaglandin
E2. J. Immunol. 188, 21–28.
27. Mathias, J.R., Dodd, M.E., Walters, K.B., Yoo, S.K., Ranheim, E.A., and
Huttenlocher, A. (2009). Characterization of zebrafish larval inflamma-
tory macrophages. Dev. Comp. Immunol. 33, 1212–1217.
28. Nakanishi, Y., Nakatsuji, M., Seno, H., Ishizu, S., Akitake-Kawano, R.,
Kanda, K., Ueo, T., Komekado, H., Kawada, M., Minami, M., and
Chiba, T. (2011). COX-2 inhibition alters the phenotype of tumor-associ-
ated macrophages from M2 to M1 in ApcMin/+ mouse polyps.
Carcinogenesis 32, 1333–1339.
Current Biology Vol 22 No 13
1258
29. Westerfield, M. (2000). The zebrafish book. A guide for the laboratory
use of zebrafish (Danio rerio), 4th ed (Eugene, OR: The University of
Oregon Press).
30. Santoriello, C., Gennaro, E., Anelli, V., Distel, M., Kelly, A., Köster, R.W.,
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